Modified-Release Oral Minoxidil for Stable Serum Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of minoxidil for treating hair loss do not provide controlled release profiles, leading to variable absorption and potential adverse effects due to peak serum concentrations.
Innovation Solution
A modified release formulation of minoxidil that releases 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, ensuring a steady state plasma concentration for effective hair growth promotion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation of minoxidil is used, then rapid absorption occurs, but peak serum concentrations cause adverse effects
Solution Approach 1:
The patent applies dynamic release control by using a modified release formulation that adjusts the release rate of minoxidil over time. The formulation transitions from initial release to sustained release, dynamically controlling the drug concentration profile to avoid peak serum concentrations while maintaining therapeutic levels, thereby reducing adverse effects associated with immediate release formulations.
Solution Approach 2:
The patent changes the release rate parameter of minoxidil from immediate to modified release. By altering the formulation parameters (using specific release mechanisms and matrices), the drug releases at a controlled rate, preventing sudden peak concentrations that cause adverse effects while still achieving therapeutic serum levels for hair growth promotion.
2Loss of time
If immediate release formulation of minoxidil is used, then quick therapeutic effect is achieved, but variable absorption reduces consistency
Solution Approach 1:
The patent implements continuous useful action through modified release formulation that provides sustained delivery of minoxidil. Instead of a single immediate release pulse, the formulation continuously releases the drug at a controlled rate, maintaining steady serum concentrations over an extended period. This continuous delivery ensures consistent therapeutic effect for hair growth while eliminating the variability associated with immediate release absorption.
3Stability of the object's composition
If modified release formulation is used to control release, then serum concentration stability improves, but formulation complexity increases
Solution Approach 1:
The patent achieves serum concentration stability by changing the release rate parameter through modified formulation design. By incorporating specific release-controlling materials and mechanisms, the formulation provides controlled release of minoxidil, maintaining stable serum levels. The complexity is managed through established pharmaceutical formulation techniques, balancing the need for stability with manufacturability and clinical practicality.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.